Category: Technology Licenses
Created On: 2022-04-28
Record Count: 7
- Drug Discovery
- Viral Infection
- HIV / AIDs
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 113052
The company is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. The Company maintains two active business segments BioTherapeutics and Vaccines/BioDefense.
The Companyâ€™s BioTherapeutics business segment is developing a first-in-class photodynamic therapy (SGX301) utilizing safe visible light for the treatment of cutaneous T-cell lymphoma (â€œCTCLâ€), proprietary formulations of oral beclomethasone 17, 21-dipropionate (â€œBDPâ€) for the prevention/treatment of gastrointestinal (â€œGIâ€) disorders characterized by severe inflammation, including pediatric Crohnâ€™s disease (SGX203) and acute radiation enteritis (SGX201), and itâ€™s novel innate defense regulator (â€œIDRâ€) technology dusquetide (SGX942) for the treatment of oral mucositis in head and neck cancer.
The Companyâ€™s Vaccines/BioDefense business segment includes active development programs for RiVaxâ„¢, its ricin toxin vaccine candidate, VeloThraxâ„¢, an anthrax vaccine candidate, OrbeShieldÂ®, a GI acute radiation syndrome (â€œGI ARSâ€) therapeutic candidate and SGX943, a melioidosis therapeutic candidate. The development of the vaccine programs currently supported by the heat stabilization technology, known as ThermoVaxÂ®, under existing and on-going government contract funding. With the government contract from the National Institute of Allergy and Infectious Diseases (â€œNIAIDâ€), the Company will attempt to advance the development of RiVaxâ„¢ to protect against exposure to ricin toxin. The Company plans to use the funds received under the government contracts with the Biomedical Advanced Research and Development Authority (â€œBARDAâ€) and NIAID to advance the development of OrbeShieldÂ® for the treatment of GI ARS.
IPSCIO Record ID: 264264
ThermoVaxÂ® is a novel method of rendering aluminum salt, (known colloquially as Alum), adjuvanted vaccines stable at elevated temperatures. Alum is the most widely employed adjuvant technology in the vaccine industry. The value of ThermoVaxÂ® lies in its potential ability to eliminate the need for cold chain production, transportation, and storage for Alum adjuvanted vaccines. This would relieve the high costs of producing and maintaining vaccines under refrigerated conditions. Based on historical reports from the World Health Organization and other scientific reports, we believe that a meaningful proportion of vaccine doses globally are wasted due to excursions from required cold chain temperature ranges. This is due to the fact that most Alum adjuvanted vaccines need to be maintained at between 2 and 8 degrees Celsius (â€œCâ€) and even brief excursions from this temperature range (especially below freezing) usually necessitates the destruction of the product or the initiation of costly stability programs specific for the vaccine lots in question. ThermoVaxÂ® has the potential to facilitate easier storage and distribution of strategic national stockpile vaccines for ricin exposure in emergency settings.
The development of the vaccine programs currently is supported by our heat stabilization technology. The focus is on developing and commercializing products to treat rare diseases where there is an unmet medical need.
Proof-of-concept preclinical studies with ThermoVaxÂ® indicate that it is able to produce stable vaccine formulations using adjuvants, protein immunogens, and other components that ordinarily would not withstand long temperature variations exceeding customary refrigerated storage conditions. These studies were conducted with our aluminum-adjuvanted ricin toxin vaccine, RiVaxÂ® and our aluminum-adjuvanted anthrax vaccine, VeloThraxÂ®.
IPSCIO Record ID: 70207
Cutaneous T-cell lymphoma (CTCL) is a class of non-Hodgkinâ€™s lymphoma (NHL), a type of cancer of the white blood cells that are an integral part of the immune system.
In addition to issued and pending patents, we also have â€œOrphan Drugâ€ designations for SGX301 in the U.S.
The exclusive license includes rights to several issued US patents, including U.S. patent numbers 6,867,235 and 7,122,518, among other domestic and foreign patent applications.
IPSCIO Record ID: 3266
IPSCIO Record ID: 248394
Anthrax Vaccine Dose shall mean the quantity of a formulation containing Anthrax Vaccine given to an individual in a single immunization.
Licensed Product shall mean an Anthrax Vaccine Dose the manufacture, use, sale, keeping, importing or exporting of which would, in the absence of the license granted under this Agreement, constitute an infringement of the Patents or that uses other Intellectual Property.
The patent is for Expression System (Anthrax Immuuogenic Polypeptide), a UK Priority Patent Application.
Recombinant Bacillus Anthracis (Anthrax) Protective Antigen Vaccine containing Alum
The patent covers MOD Case P1454 Expression System.
PharmAthene is a biodefense company engaged in the development and commercialization of medical countermeasures against biological and chemical weapons.
IPSCIO Record ID: 306663
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 is the strain of coronavirus that causes coronavirus disease 2019 (COVID-19), the respiratory illness responsible for the COVID-19 pandemic.
IPSCIO Record ID: 257492
With this amendment the parties wish to amend the Agreement to provide for the reversion of rights to Licensor under the Licensor patent rights and know-how for Influenza vaccine, HPV vaccine and HSV vaccine.
As of the Amendment Effective Date, the license granted to Licensee, and the rights and obligations of Licensee and Licensor arising therefrom, shall no longer apply to Influenza vaccine, HPV Vaccine and HSV Vaccine, and these vaccines shall no longer be deemed to be Licensed Products under the Agreement.
Hereby amended Licensor grants to Licensee an exclusive license, even as to Licensor, under Licensor know-how and patent rights to develop, make, have made, use and sell Licensed products in the Territory with the right to grant sub licenses to Affiliates of Licensee and those persons or entities through whom Licensee, in the normal course of its business collaborates in the manufacture and sale of its products; provided however, that nothing in this Agreement shall prohibit Licensor from utilizing the Licensor know-how and/or patent rights, exclusive of Licensee know-how, to develop, make, have made, use and sell, either by itself or with one or more third parties, products for the treatment of infectious diseases provided, further, notwithstanding the preceding proviso, that Licensor shall not have any right to develop, make, have made, use, or sell, either by itself or with one or more third parties, Treatment Vaccines.
Licensor grants an option to obtain a license under theLicensor patent rights and know-how to make, have made, use, sell, offer to sell and import Cancer Vaccines in the Territory for up to three (3) Cancer targets. Such Cancer target license shall be exclusive, even as to Licensor, for each Cancer Target so licensed, and shall be sublicenseable by Licensee pursuant to the terms applicable to Licensed Products.
Treatment vaccines means a bulk or finished vaccine.